Chengdu Kanghong Pharmaceutical Group Co Ltd
SZSE:002773
Income Statement
Earnings Waterfall
Chengdu Kanghong Pharmaceutical Group Co Ltd
Revenue
|
4.2B
CNY
|
Cost of Revenue
|
-509m
CNY
|
Gross Profit
|
3.7B
CNY
|
Operating Expenses
|
-2.4B
CNY
|
Operating Income
|
1.3B
CNY
|
Other Expenses
|
-133m
CNY
|
Net Income
|
1.1B
CNY
|
Income Statement
Chengdu Kanghong Pharmaceutical Group Co Ltd
Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||||||||||||||||
Revenue |
1 865
N/A
|
2 016
+8%
|
2 074
+3%
|
2 197
+6%
|
2 348
+7%
|
2 434
+4%
|
2 540
+4%
|
2 658
+5%
|
2 745
+3%
|
2 809
+2%
|
2 787
-1%
|
2 845
+2%
|
2 801
-2%
|
2 870
+2%
|
2 917
+2%
|
2 935
+1%
|
3 053
+4%
|
3 145
+3%
|
3 257
+4%
|
3 173
-3%
|
3 132
-1%
|
3 196
+2%
|
3 295
+3%
|
3 577
+9%
|
3 802
+6%
|
3 792
0%
|
3 605
-5%
|
3 586
-1%
|
3 469
-3%
|
3 392
-2%
|
3 389
0%
|
3 379
0%
|
3 546
+5%
|
3 756
+6%
|
3 957
+5%
|
4 165
+5%
|
|
Gross Profit | |||||||||||||||||||||||||||||||||||||
Cost of Revenue |
(245)
|
(254)
|
(226)
|
(268)
|
(278)
|
(279)
|
(244)
|
(298)
|
(313)
|
(319)
|
(270)
|
(311)
|
(285)
|
(278)
|
(232)
|
(270)
|
(281)
|
(292)
|
(265)
|
(309)
|
(321)
|
(350)
|
(331)
|
(404)
|
(433)
|
(428)
|
(356)
|
(418)
|
(421)
|
(417)
|
(392)
|
(441)
|
(457)
|
(478)
|
(439)
|
(509)
|
|
Gross Profit |
1 621
N/A
|
1 762
+9%
|
1 849
+5%
|
1 929
+4%
|
2 069
+7%
|
2 155
+4%
|
2 296
+7%
|
2 360
+3%
|
2 432
+3%
|
2 490
+2%
|
2 516
+1%
|
2 534
+1%
|
2 516
-1%
|
2 592
+3%
|
2 686
+4%
|
2 665
-1%
|
2 771
+4%
|
2 853
+3%
|
2 993
+5%
|
2 864
-4%
|
2 812
-2%
|
2 846
+1%
|
2 965
+4%
|
3 173
+7%
|
3 369
+6%
|
3 364
0%
|
3 250
-3%
|
3 168
-3%
|
3 048
-4%
|
2 975
-2%
|
2 997
+1%
|
2 938
-2%
|
3 089
+5%
|
3 279
+6%
|
3 519
+7%
|
3 656
+4%
|
|
Operating Income | |||||||||||||||||||||||||||||||||||||
Operating Expenses |
(1 260)
|
(1 360)
|
(1 441)
|
(1 482)
|
(1 603)
|
(1 683)
|
(1 780)
|
(1 797)
|
(1 869)
|
(1 869)
|
(1 761)
|
(1 728)
|
(1 683)
|
(1 777)
|
(1 965)
|
(1 940)
|
(1 994)
|
(2 053)
|
(2 227)
|
(2 145)
|
(2 061)
|
(2 051)
|
(3 539)
|
(3 694)
|
(3 893)
|
(3 956)
|
(2 741)
|
(2 781)
|
(2 572)
|
(2 482)
|
(2 065)
|
(2 025)
|
(2 162)
|
(2 232)
|
(2 354)
|
(2 384)
|
|
Selling, General & Administrative |
(1 259)
|
(1 359)
|
(1 320)
|
(1 482)
|
(1 602)
|
(1 682)
|
(1 639)
|
(1 791)
|
(1 866)
|
(1 838)
|
(1 626)
|
(1 648)
|
(1 647)
|
(1 691)
|
(1 789)
|
(1 824)
|
(1 821)
|
(1 861)
|
(1 989)
|
(1 932)
|
(1 843)
|
(1 869)
|
(1 908)
|
(1 942)
|
(1 955)
|
(1 935)
|
(1 792)
|
(1 801)
|
(1 760)
|
(1 700)
|
(1 713)
|
(1 696)
|
(1 808)
|
(1 888)
|
(1 896)
|
(2 032)
|
|
Research & Development |
0
|
0
|
(99)
|
0
|
0
|
0
|
(122)
|
0
|
0
|
(31)
|
(192)
|
0
|
0
|
(169)
|
(221)
|
(189)
|
(243)
|
(266)
|
(276)
|
(286)
|
(290)
|
(256)
|
(1 656)
|
(1 828)
|
(2 018)
|
(2 101)
|
(983)
|
(866)
|
(696)
|
(661)
|
(352)
|
(388)
|
(412)
|
(398)
|
(399)
|
(417)
|
|
Depreciation & Amortization |
0
|
0
|
(19)
|
0
|
0
|
0
|
(18)
|
0
|
0
|
0
|
(16)
|
0
|
0
|
0
|
(28)
|
0
|
0
|
0
|
(35)
|
0
|
0
|
0
|
(48)
|
0
|
0
|
0
|
(68)
|
0
|
0
|
0
|
(68)
|
0
|
0
|
0
|
(127)
|
0
|
|
Other Operating Expenses |
(1)
|
(1)
|
(3)
|
0
|
(1)
|
(2)
|
(0)
|
(6)
|
(3)
|
0
|
73
|
(80)
|
(36)
|
84
|
73
|
73
|
70
|
75
|
74
|
73
|
73
|
74
|
74
|
77
|
80
|
80
|
101
|
(114)
|
(117)
|
(121)
|
68
|
59
|
58
|
53
|
68
|
65
|
|
Operating Income |
360
N/A
|
402
+12%
|
408
+1%
|
447
+10%
|
466
+4%
|
472
+1%
|
517
+9%
|
563
+9%
|
563
+0%
|
621
+10%
|
756
+22%
|
805
+7%
|
833
+3%
|
815
-2%
|
721
-12%
|
724
+0%
|
778
+7%
|
800
+3%
|
766
-4%
|
719
-6%
|
751
+4%
|
795
+6%
|
(574)
N/A
|
(520)
+9%
|
(524)
-1%
|
(591)
-13%
|
508
N/A
|
388
-24%
|
476
+23%
|
493
+4%
|
932
+89%
|
913
-2%
|
927
+2%
|
1 046
+13%
|
1 164
+11%
|
1 272
+9%
|
|
Pre-Tax Income | |||||||||||||||||||||||||||||||||||||
Interest Income Expense |
21
|
24
|
30
|
29
|
31
|
35
|
40
|
43
|
47
|
52
|
61
|
55
|
68
|
73
|
75
|
79
|
66
|
61
|
55
|
50
|
51
|
54
|
62
|
63
|
67
|
64
|
62
|
63
|
63
|
69
|
83
|
87
|
98
|
95
|
97
|
100
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
(29)
|
0
|
(29)
|
0
|
(0)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
(215)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
(1)
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
4
|
1
|
20
|
17
|
15
|
18
|
17
|
17
|
15
|
8
|
(24)
|
(25)
|
(6)
|
(3)
|
3
|
3
|
(17)
|
(5)
|
17
|
30
|
35
|
25
|
(5)
|
(23)
|
(24)
|
(2)
|
38
|
40
|
45
|
24
|
15
|
14
|
(1)
|
(3)
|
(26)
|
(27)
|
|
Pre-Tax Income |
385
N/A
|
427
+11%
|
456
+7%
|
492
+8%
|
512
+4%
|
524
+2%
|
568
+8%
|
623
+10%
|
626
+0%
|
680
+9%
|
763
+12%
|
834
+9%
|
866
+4%
|
885
+2%
|
800
-10%
|
806
+1%
|
827
+3%
|
856
+4%
|
835
-2%
|
799
-4%
|
837
+5%
|
873
+4%
|
(520)
N/A
|
(480)
+8%
|
(481)
0%
|
(529)
-10%
|
393
N/A
|
491
+25%
|
584
+19%
|
587
+0%
|
1 030
+76%
|
1 014
-2%
|
1 024
+1%
|
1 138
+11%
|
1 234
+8%
|
1 345
+9%
|
|
Net Income | |||||||||||||||||||||||||||||||||||||
Tax Provision |
(67)
|
(72)
|
(59)
|
(61)
|
(65)
|
(65)
|
(68)
|
(74)
|
(71)
|
(77)
|
(119)
|
(136)
|
(145)
|
(150)
|
(105)
|
(106)
|
(102)
|
(116)
|
(117)
|
(115)
|
(124)
|
(128)
|
250
|
267
|
297
|
333
|
28
|
(7)
|
(49)
|
(69)
|
(164)
|
(167)
|
(173)
|
(206)
|
(203)
|
(220)
|
|
Income from Continuing Operations |
318
|
355
|
397
|
431
|
448
|
460
|
500
|
549
|
555
|
604
|
644
|
699
|
721
|
735
|
695
|
700
|
725
|
741
|
718
|
684
|
713
|
745
|
(270)
|
(213)
|
(184)
|
(196)
|
421
|
484
|
534
|
518
|
866
|
847
|
852
|
932
|
1 031
|
1 125
|
|
Income to Minority Interest |
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
5
|
31
|
32
|
33
|
35
|
14
|
14
|
|
Net Income (Common) |
315
N/A
|
352
+12%
|
394
+12%
|
428
+9%
|
444
+4%
|
455
+3%
|
497
+9%
|
546
+10%
|
552
+1%
|
602
+9%
|
644
+7%
|
699
+8%
|
721
+3%
|
735
+2%
|
695
-5%
|
700
+1%
|
725
+4%
|
741
+2%
|
718
-3%
|
684
-5%
|
713
+4%
|
745
+5%
|
(270)
N/A
|
(213)
+21%
|
(184)
+14%
|
(196)
-6%
|
421
N/A
|
485
+15%
|
538
+11%
|
523
-3%
|
897
+72%
|
879
-2%
|
885
+1%
|
967
+9%
|
1 045
+8%
|
1 139
+9%
|
|
EPS (Diluted) |
0.36
N/A
|
0.4
+11%
|
0.48
+20%
|
0.5
+4%
|
0.52
+4%
|
0.53
+2%
|
0.57
+8%
|
0.62
+9%
|
0.62
N/A
|
0.68
+10%
|
0.74
+9%
|
0.8
+8%
|
0.83
+4%
|
0.84
+1%
|
0.79
-6%
|
0.8
+1%
|
0.83
+4%
|
0.85
+2%
|
0.82
-4%
|
0.78
-5%
|
0.81
+4%
|
0.85
+5%
|
-0.31
N/A
|
-0.25
+19%
|
-0.2
+20%
|
-0.21
-5%
|
0.46
N/A
|
0.53
+15%
|
0.58
+9%
|
0.57
-2%
|
0.98
+72%
|
0.96
-2%
|
0.96
N/A
|
1.05
+9%
|
1.14
+9%
|
1.24
+9%
|